Impact of lung cancer treatment on physical functioning
Physical Functioning Throughout Lung Cancer Treatment
This study looks at how different lung cancer treatments affect the physical abilities and quality of life of patients to see what changes happen during and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | Hasselt University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Genk) |
| Trial ID | NCT02493114 on ClinicalTrials.gov |
What this trial studies
This observational trial investigates how lung cancer treatment affects patients' physical status, symptoms, and quality of life. It will follow a sample of 150 lung cancer patients undergoing various treatments, including surgery, chemotherapy, radiotherapy, and immunotherapy. Assessments will be conducted before, during, and after treatment to evaluate changes in exercise capacity and muscle strength, as well as the relationship between physical status and other health factors. The study aims to provide insights into the mechanisms behind deconditioning in lung cancer patients.
Who should consider this trial
Good fit: Ideal candidates are lung cancer patients undergoing treatment with a WHO performance status of 2 or less.
Not a fit: Patients with other significant health issues, such as unstable cardiac disease or orthopedic conditions that impair function, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for maintaining physical function in lung cancer patients during treatment.
How similar studies have performed: Preliminary evidence suggests that similar studies have indicated declines in physical function during lung cancer treatment, but this specific investigation into underlying causes is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * undergoing treatment (surgery, chemotherapy, immunotherapy, radiotherapy, and combination of the previous ones) * WHO performance status of maximal 2 Exclusion Criteria: * presence of other neoplasms in the last 2 years * bone metastasis * progressive neuromuscular and neurological diseases * unstable cardiac disease * pulmonary hypertension * interstitial lung disease * orthopedic conditions that significantly impair functional status * mental or psychiatric disorders that impair the ability to comply with study procedures. * a history of cerebrovascular accident with remaining functional consequences * a history of lung cancer * difficulties in understanding and speaking Dutch
Where this trial is running
Genk
- Ziekenhuis Oost-Limburg — Genk, Belgium (Recruiting)
Study contacts
- Study coordinator: Chris Burtin, PhD
- Email: chris.burtin@uhasselt.be
- Phone: 0032499387898
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.